Phase 2 Psoriasis Trial, Recruiting NCT07194200 Sponsor: Shenzhen People's Hospital Condition: Psoriasis
Back to Psoriasis

Phase 2 Psoriasis Trial, Recruiting

NCT07194200
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People with a psoriasis severity score (called a PASI score) of less than 10, meaning their psoriasis is considered mild
  • People who have been fully informed about the study and have agreed to take part by signing a consent form
  • People aged between 18 and 60 years old who are in generally good health
  • People who have not taken any medications in the past 6 months
  • People who do not have any inflammatory or immune-related skin conditions, local skin infections, or nerve and muscle diseases

Who may not be able to join:

  • People who have a type of psoriasis other than the type being studied, or who have severe psoriasis
  • People whose skin condition is currently in an active flare, or who have other serious medical conditions
  • People whom the researchers consider unsuitable for the trial — for example, those who may not be able to reliably follow or understand the study requirements (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 7 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +86 13873143466

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Shenzhen People's Hospital
Registry
ClinicalTrials.gov
Start date
15 December 2025
Est. completion
25 June 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Transepidermal Water Loss(TEWL); General appearance photography; Dermoscopic photography; Completion of self-assessment questionnaires; Adverse reactions

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 7 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov